For ELISA: Use at a concentration of 2 - 2.5μg/ml. For Neut: Use at a concentration of 10 - 12μg/ml. Neutralizes ~50-75% of IGF-I receptor-mediated rhIGF-I biological activity in MCF7 cells. Will block cell surface IGF-I receptor mediated IGF-I and IGF-II bioactivities. For WB: Use at a concentration of 1 - 2 μg/ml under non reducing conditions. Predicted molecular weight: 155 kDa. Optimal dilutions/concentrations should be determined by the researcher.
Recombinant IGFI or MCF7 cells
Does not cross-react with human recombinant IGFI bp1, human recombinant IGFI and human recombinant IGFII.
From PBS, 20 mM ammonium bicarbonate, =5% trehalose, 100 μg BSA Reconstitute with sterile PBS to the desired concentration.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
recombinant human IGFIR Glu31-Asn932 of accession # P08069
Protein G affinity purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Insulin Like Growth Factor 1 Receptor,Cd221,Igfir,Igfr,Jtk13,Igf1R
This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, May 2014]